Susceptibility profile of Aeromonas spp. from clinical strains isolated in French Guiana
Abstract
Aeromonas spp. are gram-negative bacilli of the Gammaproteobacteria class and Aeromonadaceae family. These bacteria are a public health challenge, particularly in South America. They harbor chromosomal β-lactamases belonging to classes B, C, and D, whose presence varies among species. This retrospective study aimed to evaluate the minimum inhibitory concentrations (MICs) of piperacillin-tazobactam (PTZ) and cefotaxime (CTX) for clinical strains of Aeromonas spp. A secondary objective was to assess the resistance profile of these strains to cefepime (FEP), aztreonam (AZT), ciprofloxacin (CIP), levofloxacin (LEV), and trimethoprim-sulfamethoxazole (SXT). The study was conducted at the Microbiology Laboratory of Cayenne Hospital (French Guiana) from January 2020 to December 2023. All isolated clinical Aeromonas strains, regardless of species or sample type, were included. In total, 99 strains were analyzed, comprising Aeromonas hydrophila (n = 79), Aeromonas caviae (n = 10), Aeromonas veronii (n = 6), and other Aeromonas spp. (n = 4). The median PTZ MIC was 0.5 mg/L for Aeromonas spp. overall, with six strains (6%) exhibiting MICs of >8 mg/L. For A. hydrophila, the median PTZ MIC was also 0.5 mg/L, lower than the median reported by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for strains of 4 mg/L. For CTX, the median MIC for all Aeromonas spp. was 0.064 mg/L, with four strains (4%) having MICs of >4 mg/L. The median ceftazidime (CAZ) MIC was 0.125…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 79 participants or records.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.